Panelists:
Nik Ekman
Application Development Manager
CPC
Panelist
Nik Ekman
Nik Ekman is the application development manager for Cell & Gene Therapy covering the Americas at CPC. Ekman has 10 years of experience in applications engineering and process development within the biopharma and cell & gene therapy industries. Before Ekman’s career at CPC, he was an applications engineering strategic specialist at Meissner Filtration Products, where he worked with end-users to optimize their single-use platforms and help expand the knowledge of single-use processing throughout the industry. Ekman graduated from Cal Poly SLO with a degree in biomedical engineering.
- Time:
Delivering advanced therapies to patients who need them requires an effective transition from lab-based cell therapy activity to manufacturing at scale. Robust, reproducible processes that can adapt to increasing demand is key to ensure success from early-stage research to commercial production.
In this GEN webinar, Nik Ekman will discuss critical considerations for scaling cell therapy processes from research through commercialization. During the webinar, you will learn how designing flexible, closed, compliant workflows early drives efficiency, quality, and sterility assurance across cell therapy development. Some key takeaways from the webinar include:
- Key scaling considerations through each stage of the cell therapy development pipeline—from preclinical research and clinical trials to commercialization.
- The impact of designing scalable and flexible workflows early in development to ensure efficiency, quality, and regulatory compliance later in the product lifecycle.
- The role of sterile connector technology for enabling closed-system processing to support sterility assurance and reduce risk across critical cell therapy applications.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
The post Scaling Cell Therapy Development from Research to Commercialization appeared first on GEN – Genetic Engineering and Biotechnology News.
